The promise of adeno-associated virus vectors: Will AAV provide gene therapy with a safer, more efficient delivery vehicle?

Nature Biotechnology

Volumn 14, Issue 13, 1996, Pages 1725-1726

  Carter, Barrie J ^a  

^a Targeted Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR;

ADENOVIRUS; CLINICAL TRIAL; DEFECTIVE VIRUS; GENE EXPRESSION; GENE THERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRUS GENOME;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE;

EID: 0029829007     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1296-1725     Document Type: Article

References (10)

1. McKeon, C. and Samulski, R.J. 1996 Hum. Gene Then 7:1615-1619.
2. Flotte, T. etal. 1996. Ped. Pulmonol., Suppl. 13:275.
3. Wagner, J.A. et al. 1996. Pad. Pulmonol., Suppl. 13:276.
4. Flotte, T and Carter, B.J. 1995. Gene Therapy 2:357-362.
5. Afione, S.A. et al. 1996. J. Virol. 70:3235-3241.
6. Alexander, I. E. etal. 1994. J. Virol. 68:8282-8287.
7. Ferrari, F.K. et al. 1996. J. Virol. 70:3227-3234.
8. Fisher, K.J., et al. 1996. J. Virol. 70:520-523.
9. Conrad, C.K. et al. Gene Therapy 3:658-668.
10. Xiao X. et al. 1996. J. Virol. 70:8098-8108.